Status:

COMPLETED

Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19

Lead Sponsor:

Vir Biotechnology, Inc.

Collaborating Sponsors:

GlaxoSmithKline

Conditions:

Covid19

Eligibility:

All Genders

18-69 years

Phase:

PHASE2

Brief Summary

This is a phase 2 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 (Sotrovimab) Generation 1 (Gen1) or VIR-7831 (Sotrovimab) Generation 2 (Gen2) and will be asses...

Eligibility Criteria

Inclusion

  • For Part A, participants must be aged 18 years or older at the time of obtaining informed consent
  • For Parts B and C, participants must be aged between 18 years and 69 years old at the time of obtaining informed consent
  • Participants who have a positive SARS-CoV-2 test result ≤7 days prior to enrollment and oxygen saturation ≥94% on room air and have COVID-19 symptoms and ≤7 days from onset of symptoms

Exclusion

  • Currently hospitalized or judged by the investigator as likely to require hospitalization in the next 24 hours
  • Symptoms consistent with severe COVID-19
  • Participants who, in the judgement of the investigator are likely to die in the next 7 days.
  • Severely immunocompromised participants
  • For Parts A and B, prior receipt of a SARS-CoV-2 vaccine at any time prior to enrollment (vaccination with an authorized or approved SARS-CoV-2 vaccine will not be allowed for 90 days after dosing)
  • For Parts B and C, conditions that would prohibit receipt of IM injections in the investigator's opinion
  • For Parts A, B and C, receipt of any vaccine within 48 hours prior to enrollment (vaccination with an authorized or approved SARS-CoV-2 vaccine will not be allowed for 90 days after dosing)

Key Trial Info

Start Date :

February 18 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 6 2022

Estimated Enrollment :

354 Patients enrolled

Trial Details

Trial ID

NCT04779879

Start Date

February 18 2021

End Date

April 6 2022

Last Update

May 3 2023

Active Locations (31)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (31 locations)

1

Investigative Site

Anniston, Alabama, United States, 36207

2

Investigative Site

Bakersfield, California, United States, 93301

3

Investigative Site

Northridge, California, United States, 91325

4

Investigative Site

Ft. Pierce, Florida, United States, 34982